MONTREAL, Sept. 4, 2024 /CNW/ - AbbVie (NYSE: ABBV) today announced that Canada's Drug Agency (CDA, formerly CADTH) has recommended that VRAYLAR be reimbursed with conditions, for the treatment of schizophrenia in adults.
Read more at newswire.cahello world
Provided Content: Content provided by Newswire.ca. The Globe and Mail was not involved, and material was not reviewed prior to publication.
